TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cholestasis Reversal: Efficacy of IV Fish Oil

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients will be PN dependent (unable to meet nutritional needs solely by enteral nutrition) and are expected to require PN for at least another 30 days~2. Patients considered eligible for study participation must have parenteral nutrition associated liver disease (PNALD) as defined as a direct bilirubin of \> 2 mg/dl or currently on Omegaven through another protocol. Other causes of liver disease should be excluded. A liver biopsy is not necessary for treatment.~3. Direct bilirubin \> 2.0 mg/dl or already on Omegaven through another protocol~4. Signed patient informed consent.~5. The patient must have utilized standard therapies to prevent the progression of his/her liver disease including surgical treatment, cyclic PN, avoiding overfeeding, reduction/removal of copper and manganese from PN, advancement of enteral feeding, and the use of ursodiol (i..e., Actigall®).~Exclusion Criteria:~1. Pregnancy~2. Other causes of chronic liver disease (Hepatitis C, biliary atresia, and alpha 1 anti-trypsin deficiency).~3. Enrollment in any other clinical trial involving an investigational agent (unless approved by the designated physicians on the multidisciplinary team)~4. The parent or guardian or child unwilling to provide consent or assent~In rare instances, patients diagnosed with PNALD may later be found to have liver disease due to other causes in addition to the use of PN (i.e., inborn errors of metabolism, viral infections ). Such causes may not be known at the time of enrollment and will not preclude them from continuing in the study. For the sake of statistical analysis, however, these patients will be excluded although all data will be collected and reviewed.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Omegaven (Type: EXPERIMENTAL): 1g/kg/day for duration of study participation for all participants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Osteonecrosis~* planned decompression surgery with autologous stem cell transplant~Exclusion Criteria:~* Contraindications for magnetic resonance imaging~* Hemosiderosis/hemochromatosis ( patients can still be included in the non-ferumoxytol arm)

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Ferumoxytol-enhanced MRI (Type: ACTIVE_COMPARATOR): Patients receive a ferumoxytol injection (Feraheme, AMAG, 5mg Fe/kg, single administration) prior to routine decompression surgery and autologous stem cell transplant. Follow-up imaging with magnetic resonance imaging will be conducted in regular intervals for evaluation of the response to treatment.
- Non-ferumoxytol enhanced MRI (Type: SHAM_COMPARATOR): Patients scheduled for routine decompression surgery and autologous stem cell transplant will receive follow-up magnetic resonance imaging in regular intervals for evaluation of the response to treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endothelial Function in Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥18 years with newly diagnosed obstructive sleep apnea (OSA) who were never treated with CPAP. OSA is defined as apnea-hypopnea index (AHI) ≥5 events/hour of sleep.~Exclusion Criteria:~* A history of coronary artery disease, heart failure, stroke, diabetes, malignancy, chronic pulmonary, kidney or rheumatologic disease, muscle pain/fatigue, smoking within the past 5 years, regular use of any medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
- Control (Type: PLACEBO_COMPARATOR): OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject currently meets the Diagnosis of Social Phobia as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition which is not secondary to another pre-existing psychiatric condition or to a medical condition.~* Liebowitz Social Anxiety Scale (LSAS) score greater than or equal to 60 at Screening.~* Score of 75 or greater on the SUD scale at one of the Performance Phase time points during either the Public Speaking or Social Interaction Challenge~* Written Informed Consent prior to commencing any study specific procedures.~* Women of child-bearing-potential must be able to commit to the consistent and correct use of an acceptable method of birth control throughout the study and have a negative serum pregnancy test result prior to study drug administration.~Exclusion Criteria:~* Use of any psychotropic medication within 30 days prior to study entry.~* Acute or chronic psychiatric disease which is the primary diagnosis (except Social Phobia) at the time of the study. Note that subjects with concurrent Generalized Anxiety Disorder (GAD) are allowed into the study provided this is not the primary diagnosis.~* Subjects with a history of psychiatric diseases such as schizophrenia, bipolar disorder, and psychosis are to be excluded.~* Presence of a clinical condition or disease, or use of a concomitant medication, that in the clinical judgment of the Investigator could place the patient at undue risk, interfere with study participation, or confound the results of the study.~* Use of substances of abuse within the year prior to study entry.~* Concomitant use of any over-the-counter, prescription product, or herbal preparation for treatment of the symptoms of social anxiety during the study and within 30 days prior to study entry and use of non-study anxiolytics such as benzodiazepines during the study and within 30 days prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PH94B intranasal spray (Type: EXPERIMENTAL): None
- Placebo intranasal spray (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM and HbA1C ≤7.5% on ≤1 non-insulin hypoglycemic agent or HbA1C ≤7.0% on ≤2 non-insulin hypoglycemic agents admitted to the hospital for a non-critical illness.~* Written informed consent.~Exclusion Criteria:~* Admitted to or expected to require admission to ICU~* Patients with a history of diabetic ketoacidosis or hyperosmolar state~* HbA1c \>7.5% at the time of admission or within 3 months before admission~* Insulin requiring before admission~* Unable to take oral food or medications~* Systemic steroid use~* Pregnancy or breastfeeding~* Women of Child-Bearing Potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and up to 4 weeks after the last dose of study drug.~* History of pancreatitis or active gallbladder disease~* End stage renal disease on dialysis~* Hypersensitivity to saxagliptin or another contraindication to DPP4 inhibitors~* Subject unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin group (Type: EXPERIMENTAL): DPP4 inhibitor therapy group will receive saxagliptin 2.5 to 5 mg daily in addition to correctional sliding scale insulin therapy before each meal and bedtime.
- Standard therapy group (Type: NO_INTERVENTION): Standard therapy group will receive basal-bolus insulin starting at a dose of 0.5 units/kg/day; given half as insulin glargine and half as insulin aspart. In addition, the standard therapy group will receive the correctional sliding scale insulin therapy before each meal and bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Minnesota HealthSolutions Cellular Car Seat Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or Females ages 18-75 years~* Has harnessed/fastened a child into a car seat in the last five (5) years~* Has a valid driver's license~Exclusion Criteria:~* Non-fluency in written and/or spoken English~* Participant cannot install a safety seat due to a physical or health limitation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Participants will harness the car seat in 3 separate scenarios with the sensor system enabled to provide feedback.
- Control (Type: OTHER): Participants will harness the car seat in 3 separate scenarios with the sensor system disabled in order to not provide feedback.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)~* At least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the years prior to screening (but not within 30 days prior to screening)~* Neurologic stability for greater than or equal to (\>/=) 30 days prior to both screening and baseline~* Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive~Exclusion Criteria:~* Primary progressive multiple sclerosis~* Disease duration of more than 10 years in patients with EDSS score less than or equal to (\</=) 2.0 at screening~* Contraindications for MRI~* Known presence of other neurological disorders which may mimic multiple sclerosis~* Pregnancy or lactation~* Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study~* History of or currently active primary or secondary immunodeficiency~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies~* Active infection, or history of or known presence of recurrent or chronic infection (for example, hepatitis B or C, Human Immunodeficiency Virus \[HIV\], syphilis, tuberculosis)~* History of progressive multifocal leukoencephalopathy~* Contraindications to or intolerance of oral or IV corticosteroids~* Contraindications to Rebif or incompatibility with Rebif use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Interferon beta-1a 44 mcg SC (Type: ACTIVE_COMPARATOR): Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
- Ocrelizumab (Type: EXPERIMENTAL): Ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Positive Airway Pressure in Preeclampsia to Reduce Blood Pressure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women with preeclampsia who receive care at the University of Michigan Hospitals~* No current use of PAP therapy.~* Willing and able to provide informed consent.~Exclusion Criteria:~* Current PAP therapy~* Any medical reason why PAP therapy may not be suitable (e.g., in patients with recent head trauma).~* Cognitively impaired and unable to understand informed consent.

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Positive Airway Pressure (compliant) (Type: EXPERIMENTAL): This arm was women who used auto-titrating positive airway pressure (APAP) for at least 4 hours per night
- Standard care (Type: NO_INTERVENTION): None
- Positive Airway Pressure (non-compliant) (Type: EXPERIMENTAL): No one was assigned to this arm, but for results data quality purposes, women assigned to PAP who were explicitly non-compliant (used less than 4 hours per night), were analyzed separately from women who were compliant with the PAP assignment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of open-angle glaucoma or ocular hypertension that is insufficiently responsive to topical beta-blockers or prostaglandin analogues in one or both eyes~* Is willing to stop other intraocular pressure (IOP)-lowering medications and switch to GANFORT® as a single agent in affected eye(s).~Exclusion Criteria:~* Reactive airway disease including bronchial asthma or a history of bronchial asthma or severe chronic obstructive pulmonary disease~* Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block, not controlled with pacemaker. Overt cardiac failure, cardiogenic shock.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GANFORT® (Type: OTHER): One drop of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) instilled in each affected eye once daily in the evening for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criteria: Subjects must be males or females 12 to 45 years of age.~* Subjects must have acne on their face.~* Female subjects of childbearing potential must have a negative pregnancy test. If sexually active, one medically acceptable forms of contraception must be practiced from baseline to the last study visit.~* Subjects must have the ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study.~* Subjects must be capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements).~* Subjects must be able to complete the study and to comply with study instructions.~Exclusion Criteria:~* Subjects who are pregnant, trying to become pregnant, or breast-feeding.~* Subjects with conditions that may influence the safety and or efficacy assessments of the study including, but not limited to: regional enteritis or inflammatory bowel disease, lupus, dermatomyositis, rosacea, seborrheic dermatitis, beard folliculitis, or perioral dermatitis, subject who are immunocompromised or have had any major illness within 30 days before the screening examination~* History of known or suspected intolerance including any known hypersensitivity or previous allergic reaction to any of the ingredients of the study products~* Subjects who have used topical antibiotics or topical steroids on the face, facial procedures, or any investigational therapy within the past 4 weeks or systemic retinoids within the past 6 months.~* Subjects who have any other disease or condition, or are using any medication, that in the judgment of the investigator would put the subject at unacceptable risk for participation in the study.~* Other exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Benzoyl peroxide/clindamycin gel + tazarotene cream
- 2 (Type: ACTIVE_COMPARATOR): Benzoyl peroxide/clindamycin gel + vehicle cream
- 3 (Type: ACTIVE_COMPARATOR): Benzoyl peroxide gel + tazarotene cream
- 4 (Type: ACTIVE_COMPARATOR): Clindamycin gel + tazarotene cream
- 5 (Type: ACTIVE_COMPARATOR): Vehicle gel+ tazarotene cream
- 6 (Type: PLACEBO_COMPARATOR): Vehicle gel + vehicle cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Cetirizine in Androgenetic Alopecia in Females

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Females with androgenetic alopecia of age 20-50 years.~2. Patients experiencing active hair loss within the last 12 months.~3. Sinclair scale 2, 3 and 4.~4. Patients willing to continue their current regimen of vitamins and nutritional supplements and not start any new vitamins or nutritional supplements for the duration of the study.~5. Patients willing to use a mild non-medicated shampoo and conditioner for the duration of the study.~6. Patients who did not receive topical or systemic treatment for androgenetic alopecia or prostaglandins in the last 6 months.~Exclusion Criteria:~* 1. Patients with a chronic dermatological condition (eczema, psoriasis, infection, etc) of the scalp other than FPHL.~  2. Subjects who had hair transplants, scalp reduction, current hair weave or tattooing in the target area, which makes it difficult to perform hair count assessment.~  3. Subjects who received radiation therapy to the scalp, or has had chemotherapy in the past year.~  4. Subjects who have a known underlying medical problem that could influence hair growth such as HIV infection, connective tissue disease, a thyroid condition, inflammatory bowel disease or other medical conditions, at the discretion of the investigator.~  5. Subjects with clinical diagnosis of alopecia areata or other non-AGA forms of alopecia.~  6. Pregnant or lactating females or planning to become pregnant for the duration of the study.~  7. Patients with severe cardiovascular disease, uncontrolled or untreated hypertension, arrythmia or clinically relevant hypotension.~  8. Subjects with hair loss for greater than 5 years, as medical therapy is unlikely to have much effect at restoring hair follicles inactive for that long of a period.~  9. The subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles.~  10. Patients using any medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Study group (Type: EXPERIMENTAL): (33) patients will apply topical minoxidil (5%) once daily and topical cetirizine (1%) once daily on their scalp for 6 months.
- Control group (Type: ACTIVE_COMPARATOR): (33) patients will apply topical minoxidil (5%) once daily and placebo once daily on their scalp for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete